Regeneron Pharmaceuticals, Inc.REGN
NASDAQ • Healthcare
$739.64
P/E
17.80
PEG
0.02
FCF Yield
—
Rev Growth YoY
+99.0% YoY
Gross Margin
8656.0%
Health Score
7/10
D/E Ratio
0.09
Confidence
LOW
Business Snapshot
Regeneron Pharmaceuticals is a US-based biopharmaceutical company focused on discovering, developing, and commercialising medicines for serious diseases, with key franchises in ophthalmology (Eylea), oncology, immunology, and rare diseases (including Dupixent, developed with Sanofi). The company operates in the large-cap biotechnology space and competes across multiple high-value therapeutic categories. Based on available valuation ratios and the current share price of $739.64, Regeneron is a well-established large-cap biotech, though a precise market capitalisation figure is not calculable from the data provided.
Financial Health
**Score: 7/10** Regeneron's balance sheet is notably conservative, with a debt-to-equity ratio of just 0.09x — indicating minimal leverage and strong financial discipline. The current ratio of 4.13x signals that the company holds more than four times current liabilities in liquid assets, suggesting robust short-term solvency...
Risk Assessment
- **DATA INTEGRITY:** Gross margin of 8,656% and net margin of 3,141% are implausible for recurring operations and strongly suggest the reported financials include non-recurring items, making year-over-year comparisons unreliable. - **FREE CASH FLOW:** FCF data is unavailable and the Python DCF model flagged negative or absent FCF, removing the single most important measure of sustainable value creation from this analysis. - **TECHNICALS:** A confirmed "death cross" pattern (50-day MA crossing below 200-day MA) is a bearish technical signal, with current price sitting below both moving averages and MACD also signalling bearish momentum. - **VALUATION ANCHORING:** The absence of a DCF fair value estimate and TTM revenue/net income figures means there is no quantitative floor or ceiling to assess whether $739.64 is justified, creating material pricing uncertainty. - **EARNINGS QUALITY:** With 3 of 4 recent quarters beating estimates — a positive signal — the extraordinary earnings growth of 848% YoY still lacks quarterly granularity to determine whether it is being sustained or reversing. ---...